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Résumé Summary
Les  conflits  d'intérêts  (CI)  et  les  conflits  d'engagement 
dans les universités ne sont pas seulement des questions 
limitées aux chercheurs universitaires ; ils peuvent devenir 
des problèmes pour les actes professionnels individuels ou 
les  décisions  au  niveau  du  personnel  administratif.  Par 
exemple, les gens associés à l'autorisation du transfert de 
technologie doivent  également  être attentifs aux CI  pour 
s'assurer  qu'ils  prennent  les  mesures  appropriées  pour 
respecter leurs engagements et pour travailler en accord 
avec les intérêts de leur employeur (l'Université) ainsi que 
les chercheurs avec lesquels ils travaillent.
Conflicts of interest (COI) and commitment in universities 
are not only issues limited to university researchers; they 
may become issues for individuals’ professional actions or 
decisions at the level of administrative staff. For example, 
people associated with technology transfer licensing also 
need  to  be  alert  to  COI,  and  to  ensure  they  take 
appropriate measures to meet their commitments and work 
in line with the interests of their employer (the University) 
and the researchers with whom they work.
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This case study is inspired by a story of interest that occurred at the University of Texas at Austin in  
December 2011 [1]. The individual and institution mentioned in this case study are fictional.
Background
Many  US  and  Canadian  universities  host  technology  transfer  offices  (TTO),  sometimes  called 
technology licensing offices or university-research partnerships offices. These offices have been put in 
place to facilitate the translation of university research findings into commercial products  [2]. The 
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development  of  TTOs  has  been  supported  over  the  past  30  years  by  both  public  and  private 
incentives to encourage universities to be proactive in moving research findings from the laboratory to 
the marketplace, to stimulate university entrepreneurship and thus economic development. 
In the United States, the Bayh-Dole Act, enacted in 1980, created a uniform patent policy among the 
many federal agencies that fund research, enabling small businesses and non-profit organizations, 
like universities, to retain title to inventions made under federally-funded research programs. Through 
such  legislation,  universities  have  an  implicit  obligation  to  collaborate  with  companies  to 
commercialize research findings arising from federal funding [3]. In Canada, federal and provincial 
governments,  mainly  through  research funding agencies,  have put  in  place numerous university-
industry partnership programs to stimulate technology transfers at the industrial level [4, 5].
TTOs act as intermediaries between industry,  universities and researchers to assess the potential 
economic value of research findings, so that they can be translated into commercial products. While 
research findings may prove to have a potential  economic value,  they are often unproven at  the 
industrial  level.  Thus  companies  must  often  commit  to  investing  further  in  both  Research  and 
Development (R&D) to bring university innovations to market.
The  TTO may  assist  researchers  in  obtaining  R&D  funding  support  (e.g.,  from  venture  capital), 
negotiating  research  contracts  and  licences  with  funding  agencies  and  industry,  filing  for  patent 
protection, and seeking industrial financial support for further development [6]. Instead of negotiating 
a  licence  agreement  with  an existing  company,  researchers  might  also  prefer  to  launch  start-up 
companies to develop an innovation because they want to be actively involved in moving it to market. 
In such a case, the TTO will work with the researcher and external venture capitalists in the creation 
of the start-up. License agreements between companies or start-ups are usually subject to upfront 
fees,  royalties  or  milestone  payments  to  the  university  (which  vary  depending  on  institutional 
intellectual property agreements). In the case of start-up companies, the university may even claim 
equity as recompense for their investment (i.e., the support of the TTO) and support of the researcher  
(i.e., the institutional research environment).
Administrative  staff  from  the  TTO  must  be  technically  trained,  have  good  communication  and 
negotiation skills, and act as “neutral” intermediaries between researchers and industry to protect the 
university’s and researcher’s intellectual property rights. It is common knowledge to people active in 
the TTO sector that they should pay attention to their institutional conflict  of interest (COI)  policy. 
Some US universities – such as Harvard University, the University of Minnesota and the University of 
North Carolina – have even implemented specific guidelines addressing the management of COI in 
technology transfer [7-9].
The Case
Eric has a PhD in mechanical engineering and is a full-time technology transfer officer in the Office for 
Technology  Licensing  and  Industry  Collaboration  (OTLIC)  at  Lewiston  University. Eric’s  activities 
include  technical  reviews,  negotiating  research  agreements  with  industry  partners,  promoting 
University researchers’ expertise and innovations to external enterprises, and facilitating the launch of 
start-up companies.
Over the past three years, Dr. Fennec – a professor in bioengineering at Lewiston – has benefited 
from important public  funding from the National  Science Funding Council  to support  some of  his 
research, specifically in the field of battery longevity for active implantable medical devices (AIMD). 
Batteries are responsible for supplying electrical energy to such devices, and they have a current 
lifetime of 3 to 8 years. Patients benefiting from battery-powered implantable devices have to undergo 
multiple  surgeries  throughout  their  lives  because  of  limited  battery  life.  AIMD  procedures  are 
expensive and risky, so increasing the lifespan of implant batteries could provide important benefits 
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both to patients (fewer surgical interventions) and to the health care system (cost savings). During the 
course of his research, Dr. Fennec developed a new power system that, according to preliminary 
findings, increases the battery lifespan of AIMD by 50%. If commercialized, Dr. Fennec anticipates 
that  this  technology  could  be  a  “game  changer”  by  making  these  devices  more  patient-friendly, 
thereby increasing their application in clinical practice. This could also generate significant revenues 
and an excellent visibility for Lewiston University and for Dr. Fennec’s research group.
Dr. Fennec sought to file a patent and a trademark for the technology he developed, called TechLight. 
According to the University Intellectual Property Policy, Dr. Fennec had to submit a patent disclosure 
to the OTLIC, and specifically to Eric who is the technology transfer officer dedicated to working with  
faculty members in the biomedical sciences. After a technical review to evaluate the patentability and 
potential  commercialization of  the technology,  Eric  worked with an external  patent  agent to file  a 
patent  application  under  the  international  Patent  Cooperation  Treaty  (PCT).  The  PCT procedure 
essentially  leads to  a  standard  national  or  regional  patent  application,  which  may be  granted or 
rejected according to applicable national laws, in each jurisdiction in which a patent is desired.
Dr. Fennec has discussed with Eric his strong interest in creating a start-up (to be named LightCo) to 
commercialize  TechLight because Dr. Fennec would like to keep control of the development of his 
technology. But Eric has some doubts about the “entrepreneurial capacities” of Dr. Fennec, who has 
absolutely no business expertise or experience working with entrepreneurs or venture capitalists. Eric 
anticipates that TechLight could be easily licensed to an already established medical device company. 
Nevertheless, Eric respects Dr. Fennec’s determination to create his own start-up and proposes that  
they meet with a representative from VenCo, a venture capital firm with which the University usually 
works under a non-exclusive agreement. The aim would be to discuss arrangements to facilitate the 
creation of the start-up LightCo, to determine the best approach to obtaining the necessary leverage 
financing to cover initial operating costs and R&D expenses, and to develop a business plan that 
could then attract further venture capital support. 
Dr. Fennec is concerned by a bad experience that one of his colleagues had with the venture capital 
firm  VenCo and so he fears losing control  of  his start-up.  Yet,  he also recognises that  he needs 
practical guidance in becoming an “academic entrepreneur”, so he has suggested to Eric that they 
could instead work with  PatCo,  a for-profit  consulting firm offering services to small  and medium 
enterprises and start-ups. PatCo provides support in developing R&D programs, preparing business 
plans,  searching  for  external  funding,  and  recruiting  professional  expertise.  In  exchange for  this 
technical and financial support, PatCo asks for up to 5% equity in their clients’ business. Dr. Fennec 
mentions to Eric that he has already met with the scientific advisor of this firm. 
Eric  expresses  concerns  over  Dr.  Fennec’s  initiative  because  his  brother,  William,  is  an  active 
founding member of PatCo who deals with the firm’s  business matters, including intellectual property 
negotiations and company registration [10, 11]. Although Eric has no direct financial interest in the 
firm, he does not feel comfortable with the fact that Dr. Fennec first consulted with PatCo and so Eric 
raises the issue with him. 
From Dr. Fennec’s point of view, the fact that Eric has no direct interest in PatCo and will not profit 
directly from the commercialization of TechLight means that there is no problem. In his professional 
judgment, Eric thinks that  TechLight could prove to be a real break-through in the field and is an 
innovation that has the potential to generate important revenues both for Dr. Fennec (via his spin-off, 
LightCo) and for Lewsiton University. Eric wants to maintain good relations with Dr. Fennec and so 
works actively  with  him throughout  the development  of  his  start-up and the commercialization  of 
TechLight  in  collaboration with  PatCo – even if  he feels  not  completely at  ease working with his 
brother’s  firm.  Eric  has  confirmed  that  according  to  the  University’s  policies,  provided  that  the 
University is compensated for Intellectual Property rights, it would be possible to initiate a technology 
transfer agreement for Dr. Fennec once the start-up has been created.
ISSN 1923-2799 3 / 5
G Mathieu BioéthiqueOnline year, 1/16
(http://bioethiqueonline.ca/1/16)
Questions to consider
1. What challenges does Eric face in meeting the expectations of both the University and its 
researchers?
2. Does  Eric’s  professional  interest  in  technology  transfer  (e.g.,  promotion)  influence  him to 
inappropriately value researchers’ innovations primarily in terms of their commercial success?
• Should  technology  transfer  focus  primarily  on  transforming  researchers’  findings  into 
profitable outcomes?
3. Once Eric has disclosed the potential  conflict of interest involving his brother William, how 
should he deal with the issue? Should he have only disclosed the conflict to Dr. Fennec or to 
his superiors as well?
4. Is there a conflict between the role of the University as a research organization and that of 
becoming  a  commercial  partner  in  innovations  when  the  time  comes  to  commercializing 
patents? 
• Could  the  technology  transfer  process  in  which  Eric  and  Dr.  Fennec are  involved  be 
blurring one of the primary missions of the University, that is, knowledge production?
5. How important is the possibility that Dr. Fennec, as an “academic entrepreneur”, may have 
conflicting  interests  and  responsibilities  with  his  role  as  a  “university  researcher”  and 
professor?
• Does Eric have any responsibility to discuss or address these issues with Dr. Fennec?
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